ACR 2022

Questions discussed in this category

What are your top takeaways from ACR 2022?

4 Answers available

Papers discussed in this category

N Engl J Med,

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.

Ann Rheum Dis, 2022 Sep 22

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.

Related Topics